Wendla Citron, MD
Radiation Oncology · Glen Burnie, MDNPI 1477588846
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 117 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 9.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $706 and has fallen 76.7% since, to $165 in 2025.
Across 117 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$240
- Daiichi Sankyo Inc.$237
- Merck$136
- Amgen$114
- Bristol Myers Squibb$107
- Boston Scientific$104
- plus $1K from 33 others
What the payments were for
- Food & beverage$2,428100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 14 | $240 |
| Daiichi Sankyo Inc. | 10 | $237 |
| Merck | 8 | $136 |
| Amgen | 6 | $114 |
| Bristol Myers Squibb | 5 | $107 |
| Boston Scientific | 4 | $104 |
| Sanofi | 5 | $96 |
| GSK | 4 | $90 |
| Varian Medical Systems, Inc. | 2 | $90 |
| Eisai Inc. | 5 | $87 |
| Taiho Oncology, Inc. | 4 | $85 |
| Exelixis Inc. | 3 | $82 |
| Bayer | 3 | $80 |
| Johnson & Johnson | 4 | $66 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| AstraZeneca | 3 | $51 |
| Mirati Therapeutics, Inc. | 2 | $51 |
| Blue Earth Diagnostics | 2 | $44 |
| Palette Life Sciences, Inc. | 1 | $44 |
| Lilly USA, LLC | 3 | $43 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Myovant Sciences Inc. | 2 | $41 |
| Tactile Systems Technology Inc | 2 | $38 |
| Genentech USA, Inc. | 2 | $37 |
| Seagen Inc. | 2 | $32 |
| AVEO Pharmaceuticals, Inc. | 2 | $31 |
| Puma Biotechnology, Inc. | 2 | $30 |
| Teleflex LLC | 1 | $30 |
| Pfizer | 1 | $28 |
| Tersera Therapeutics LLC | 2 | $28 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $27 |
| Array Biopharma Inc | 1 | $25 |
| Immunogen, Inc. | 1 | $24 |
| Deciphera Pharmaceuticals Inc. | 1 | $23 |
| Gilead | 1 | $23 |
| Clovis Oncology, Inc. | 1 | $21 |
| Agios Pharmaceuticals, Inc. | 1 | $20 |
| Foundation Medicine, Inc. | 1 | $16 |
| Telix Pharmaceuticals | 1 | $15 |
How this compares
$2,428 in reported general payments places this provider in the 75th percentile of 108 radiation oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 14 | $192 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Glen Burnie
- Akshar PatelGlen Burnie$2K
- Dan KunaprayoonGlen Burnie$734
- Sahaja AcharyaBaltimore$200K
- Arpit ChhabraBaltimore$97K
- Robert BrooklandTowson$34K
- Lawrence KleinbergBaltimore$34K
- Danny SongBaltimore$32K
- Jason MolitorisBaltimore$26K
- Kristin RedmondBaltimore$17K
- John MansuetiBerlin$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.